Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
GERN's Cash-to-Debt is ranked higher than
99% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. GERN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
GERN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.99  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.94
GERN's Equity-to-Asset is ranked higher than
93% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. GERN: 0.94 )
Ranked among companies with meaningful Equity-to-Asset only.
GERN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.41  Med: 0.87 Max: 0.96
Current: 0.94
0.41
0.96
Piotroski F-Score: 3
Altman Z-Score: 15.73
Beneish M-Score: -3.66
WACC vs ROIC
26.25%
-149.05%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -497.34
GERN's Operating Margin % is ranked lower than
70% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. GERN: -497.34 )
Ranked among companies with meaningful Operating Margin % only.
GERN' s Operating Margin % Range Over the Past 10 Years
Min: -4069.18  Med: -2842.68 Max: -1.54
Current: -497.34
-4069.18
-1.54
Net Margin % -479.34
GERN's Net Margin % is ranked lower than
70% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. GERN: -479.34 )
Ranked among companies with meaningful Net Margin % only.
GERN' s Net Margin % Range Over the Past 10 Years
Min: -4066.28  Med: -2767.01 Max: 0.13
Current: -479.34
-4066.28
0.13
ROE % -22.37
GERN's ROE % is ranked higher than
62% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. GERN: -22.37 )
Ranked among companies with meaningful ROE % only.
GERN' s ROE % Range Over the Past 10 Years
Min: -60.98  Med: -39.36 Max: 0.03
Current: -22.37
-60.98
0.03
ROA % -21.23
GERN's ROA % is ranked higher than
60% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. GERN: -21.23 )
Ranked among companies with meaningful ROA % only.
GERN' s ROA % Range Over the Past 10 Years
Min: -53.81  Med: -35.38 Max: 0.03
Current: -21.23
-53.81
0.03
ROC (Joel Greenblatt) % -15292.83
GERN's ROC (Joel Greenblatt) % is ranked lower than
90% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. GERN: -15292.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GERN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -26858.87  Med: -3815.65 Max: 70.53
Current: -15292.83
-26858.87
70.53
3-Year Revenue Growth Rate 57.40
GERN's 3-Year Revenue Growth Rate is ranked higher than
89% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. GERN: 57.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GERN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -81.5  Med: -26.3 Max: 192.4
Current: 57.4
-81.5
192.4
3-Year EBITDA Growth Rate -14.50
GERN's 3-Year EBITDA Growth Rate is ranked lower than
68% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. GERN: -14.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GERN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -35.9  Med: -4.55 Max: 13.3
Current: -14.5
-35.9
13.3
3-Year EPS without NRI Growth Rate -14.10
GERN's 3-Year EPS without NRI Growth Rate is ranked lower than
63% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. GERN: -14.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GERN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -100  Med: -14.1 Max: 23.9
Current: -14.1
-100
23.9
GuruFocus has detected 3 Warning Signs with Geron Corp $GERN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GERN's 10-Y Financials

Financials (Next Earnings Date: 2017-06-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

GERN Guru Trades in Q1 2016

Jim Simons 453,480 sh (New)
Paul Tudor Jones 104,800 sh (+620.62%)
Joel Greenblatt 466,859 sh (+55.63%)
First Eagle Investment 159,700 sh (unchged)
» More
Q2 2016

GERN Guru Trades in Q2 2016

Jim Simons 461,580 sh (+1.79%)
First Eagle Investment 159,700 sh (unchged)
Paul Tudor Jones 88,300 sh (-15.74%)
Joel Greenblatt 33,232 sh (-92.88%)
» More
Q3 2016

GERN Guru Trades in Q3 2016

Paul Tudor Jones 169,600 sh (+92.07%)
Jim Simons 515,380 sh (+11.66%)
Joel Greenblatt Sold Out
First Eagle Investment 144,700 sh (-9.39%)
» More
Q4 2016

GERN Guru Trades in Q4 2016

First Eagle Investment 144,700 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones 46,700 sh (-72.46%)
» More
» Details

Insider Trades

Latest Guru Trades with GERN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:FOMX, OTCPK:PTCHF, NAS:NVAX, OTCPK:DGJI, NAS:OBSV, NAS:OMED, NAS:PDLI, NAS:SVA, OTCPK:CNBX, NAS:BLCM, AMEX:BTX, NAS:AKBA, NAS:ADXS, NAS:CCXI, NAS:ARNA, NAS:IMGN, NAS:BSTC, NAS:VCYT, NAS:VYGR, OTCPK:THERF » details
Traded in other countries:GON.Germany,
Geron Corp is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic products for oncology such as telomerase inhibitor, imetelstat and in hematologic myeloid malignancies, among others.

Geron Corp is a clinical stage biopharmaceutical company. Its focus is the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imelstat is expected to directly obstruct malignant-cell proliferation. The company has an exclusive collaboration and license agreement with Janssen Biotech to develop and commercialize imetelstat worldwide for oncology and other human therapeutic uses.

Ratios

vs
industry
vs
history
PB Ratio 2.76
GERN's PB Ratio is ranked higher than
62% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. GERN: 2.76 )
Ranked among companies with meaningful PB Ratio only.
GERN' s PB Ratio Range Over the Past 10 Years
Min: 1.07  Med: 2.69 Max: 12.12
Current: 2.76
1.07
12.12
PS Ratio 54.36
GERN's PS Ratio is ranked lower than
75% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. GERN: 54.36 )
Ranked among companies with meaningful PS Ratio only.
GERN' s PS Ratio Range Over the Past 10 Years
Min: 11.3  Med: 123.06 Max: 620
Current: 54.36
11.3
620
EV-to-EBIT -7.56
GERN's EV-to-EBIT is ranked lower than
99.99% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. GERN: -7.56 )
Ranked among companies with meaningful EV-to-EBIT only.
GERN' s EV-to-EBIT Range Over the Past 10 Years
Min: -1775.3  Med: -4.6 Max: 5293.3
Current: -7.56
-1775.3
5293.3
EV-to-EBITDA -7.58
GERN's EV-to-EBITDA is ranked lower than
99.99% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 15.67 vs. GERN: -7.58 )
Ranked among companies with meaningful EV-to-EBITDA only.
GERN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2063.2  Med: -4.75 Max: 3733.2
Current: -7.58
-2063.2
3733.2
Current Ratio 14.76
GERN's Current Ratio is ranked higher than
90% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. GERN: 14.76 )
Ranked among companies with meaningful Current Ratio only.
GERN' s Current Ratio Range Over the Past 10 Years
Min: 3.67  Med: 7.61 Max: 21.82
Current: 14.76
3.67
21.82
Quick Ratio 14.76
GERN's Quick Ratio is ranked higher than
90% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. GERN: 14.76 )
Ranked among companies with meaningful Quick Ratio only.
GERN' s Quick Ratio Range Over the Past 10 Years
Min: 3.67  Med: 7.61 Max: 21.82
Current: 14.76
3.67
21.82
Days Sales Outstanding 28.14
GERN's Days Sales Outstanding is ranked higher than
76% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. GERN: 28.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
GERN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.1  Med: 137.65 Max: 304.85
Current: 28.14
12.1
304.85

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.80
GERN's 3-Year Average Share Buyback Ratio is ranked higher than
65% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. GERN: -6.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GERN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -37.8  Med: -13.4 Max: -2.1
Current: -6.8
-37.8
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.16
GERN's Price-to-Net-Cash is ranked higher than
72% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. GERN: 3.16 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GERN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.71  Med: 3.96 Max: 119.3
Current: 3.16
1.71
119.3
Price-to-Net-Current-Asset-Value 3.11
GERN's Price-to-Net-Current-Asset-Value is ranked higher than
72% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. GERN: 3.11 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GERN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.65  Med: 3.89 Max: 70.18
Current: 3.11
1.65
70.18
Price-to-Tangible-Book 2.76
GERN's Price-to-Tangible-Book is ranked higher than
69% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. GERN: 2.76 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GERN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.26  Med: 3.49 Max: 19.03
Current: 2.76
1.26
19.03
Price-to-Median-PS-Value 0.44
GERN's Price-to-Median-PS-Value is ranked higher than
83% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. GERN: 0.44 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GERN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.09  Med: 0.57 Max: 7.33
Current: 0.44
0.09
7.33
Earnings Yield (Greenblatt) % -13.23
GERN's Earnings Yield (Greenblatt) % is ranked lower than
57% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. GERN: -13.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GERN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -13.23  Med: 0.3 Max: 0.4
Current: -13.23
-13.23
0.4

More Statistics

Revenue (TTM) (Mil) $6.16
EPS (TTM) $ -0.19
Beta3.18
Short Percentage of Float20.25%
52-Week Range $1.81 - 3.35
Shares Outstanding (Mil)159.16
» More Articles for GERN

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
WEEKLY CFO SELLS HIGHLIGHT: HTM, OVTI, VSEA, KSWS,GERN, ATRC Jun 20 2011 
Geron Corp. Reports Operating Results (10-Q) Oct 29 2010 
Geron: Buyer Beware Oct 13 2010 
Geron Corp. (GERN) President and CEO Thomas Okarma sells 18,874 Shares Jun 03 2010 
Geron Corp. (GERN) EVP and CFO David Greenwood sells 14,746 Shares Jun 03 2010 
Banking 60% on the Day the World Changed: FDA Approves Geron to Test Embryonic Stem Cells on Humans Jan 24 2009 
The Next Boom Emerges Nov 23 2008 

More From Other Websites
Today's Research Reports on Stocks to Watch: Geron and Galena Biopharma Mar 20 2017
Geron Corp. :GERN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Mar 17 2017
Geron Corp. :GERN-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Mar 15 2017
Geron Corp. breached its 50 day moving average in a Bearish Manner : GERN-US : March 15, 2017 Mar 15 2017
GERON CORP Financials Mar 07 2017
Edited Transcript of GERN earnings conference call or presentation 1-Mar-17 9:30pm GMT Mar 03 2017
GERON CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 03 2017
Geron Announces Presentation at American Association for Cancer Research Annual Meeting Mar 02 2017
GERON CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 01 2017
Geron Corporation Reports Fourth Quarter and Annual 2016 Financial Results Mar 01 2017
GERON CORP Files SEC form 10-K, Annual Report Mar 01 2017
Q4 2016 Geron Corp Earnings Release - After Market Close Mar 01 2017
Geron Announces Conference Call to Discuss Fourth Quarter and Annual 2016 Financial Results Feb 22 2017
GERON CORP Files SEC form 8-K, Change in Directors or Principal Officers Feb 10 2017
Geron Corp. breached its 50 day moving average in a Bearish Manner : GERN-US : January 12, 2017 Jan 12 2017
Biotech Industry Off to a Strong Start in 2017 Latest Reports on Halozyme Therapeutics and Geron Jan 09 2017
GERON CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jan 09 2017
ETFs with exposure to Geron Corp. : December 29, 2016 Dec 29 2016
Geron Corp. breached its 50 day moving average in a Bullish Manner : GERN-US : December 26, 2016 Dec 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)